Kyntra Bio
KYNB
70 hedge funds and large institutions have $18.9M invested in Kyntra Bio in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 30 reducing their positions, and 38 closing their positions.
0.44% less ownership
Funds ownership: 2.27% → 1.83% (-0.44%)
15% less call options, than puts
Call options by funds: $248K | Put options by funds: $291K
31% less funds holding
Funds holding: 102 → 70 (-32)
57% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 30
63% less capital invested
Capital invested by funds: $50.4M → $18.9M (-$31.6M)
84% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$872K |
| 2 |
JP Morgan Chase
New York
|
+$820K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$463K |
| 4 |
Renaissance Technologies
New York
|
+$455K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$326K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$2.26M |
| 2 |
AC
Armistice Capital
New York
|
-$1.29M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.18M |
| 4 |
Millennium Management
New York
|
-$687K |
| 5 |
PI
Pennant Investors
Summit,
New Jersey
|
-$686K |
KYNB Hedge Fund Activity: Q3 2024 in Review
70 of the 6,977 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q3 2024, worth a combined $18.9M — down 63% from $50.4M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of KYNB and 6 opened new positions — a net loss of 32 holders — while 30 trimmed existing stakes and 13 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $872K. The largest seller was Primecap Management, cutting an estimated $2.26M.
- 70 institutional investors held Kyntra Bio (KYNB) as of Q3 2024, down from 102 in Q2 2024.
- Funds reported $18.9M of Kyntra Bio stock for Q3 2024, down 63% quarter-over-quarter.
- 6 funds opened new Kyntra Bio positions in Q3 2024 and 38 closed out, a net change of -32 holders.
- The largest Kyntra Bio buyer in Q3 2024 was Marshall Wace, an estimated $872K added.
- The largest Kyntra Bio seller in Q3 2024 was Primecap Management, an estimated $2.26M sold.
Based on aggregated 13F filings for Q3 2024.